{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:52:11Z","timestamp":1792183931641,"version":"4.4.0"},"reference-count":44,"publisher":"FapUNIFESP (SciELO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:p>Osteoporosis is a skeletal disorder characterized by compromised bone strength that predisposes a person to increased fracture risk. Fractures are often associated with increased morbidity, higher mortality, loss of function and even psychological consequences. Pharmacotherapeutic interventions (e.g., bisphosphonates, selective estrogen receptor modulators, calcitonin, and teriparatide) in women with postmenopausal osteoporosis provide substantial reduction in fracture risk over and above risk reduction with calcium and vitamin D supplementation alone. The importance of nutritional support along with an appropriate exercise regimen, avoiding smoking and excessive alcohol use is to be emphasized along with the pharmacologic approach to osteoporosis. Despite the effectiveness of therapy with pharmacologic agents, most patients who start therapy do not remain on treatment for more than 1 year.<\/jats:p>","DOI":"10.1590\/s0004-27302006000400020","type":"journal-article","created":{"date-parts":[[2006,12,12]],"date-time":"2006-12-12T12:30:21Z","timestamp":1165926621000},"page":"755-763","source":"Crossref","is-referenced-by-count":11,"title":["Update on osteoporosis therapy"],"prefix":"10.1590","volume":"50","author":[{"given":"Jo\u00e3o Lindolfo C.","family":"Borges","sequence":"first","affiliation":[{"name":"Universidade Catolica de Brasilia,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[{"name":"Columbia University,  USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4158\/EP.9.6.544","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis 2001 edition, with selected updates for 2003","volume":"9","author":"Hodgson SF","year":"2003","journal-title":"Endocr Pract"},{"key":"ref2","first-page":"84","article-title":"Management of postmenopausal osteoporosis position statement of the North American Menopause Society","volume":"9","year":"2002","journal-title":"Menopause","ISSN":"https:\/\/id.crossref.org\/issn\/1072-3714","issn-type":"print"},{"key":"ref3","series-title":"Physician's Guide to Prevention and Treatment of Osteoporosis"},{"key":"ref4","series-title":"Bone health and osteoporosis: A report of the Surgeon General Rockville, MD","year":"2004"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00198-003-1436-x","article-title":"Effects of exercise on bone mineral density in calcium-replete postmenopausal women with and without hormone replacement therapy","volume":"14","author":"Going S","year":"2003","journal-title":"Osteoporos Int","ISSN":"https:\/\/id.crossref.org\/issn\/0937-941X","issn-type":"print"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1001\/jama.1990.03440220053029","article-title":"High-intensity strength training in nonagenarians effects on skeletal muscle","volume":"263","author":"Fiatarone MA","year":"1990","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1056\/NEJM199709043371003","article-title":"Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older","volume":"337","author":"Dawson-Hughes B","year":"1997","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1056\/NEJM199009273231305","article-title":"A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women","volume":"323","author":"Dawson-Hughes B","year":"1990","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0002-9343(99)80310-6","article-title":"Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women a randomized controlled trial","volume":"98","author":"Reid IR","year":"1995","journal-title":"Am J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9343","issn-type":"print"},{"key":"ref10","series-title":"Dietary Supplement Fact Sheet"},{"key":"ref11","series-title":"Dietary Supplement Fact Sheet: Vitamin D"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/oxfordjournals.aje.a116681","article-title":"Incidence of and risk factors for falls and injurious falls among the community-dwelling elderly","volume":"137","author":"O'Loughlin JL","year":"1993","journal-title":"Am J Epidemiol","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9262","issn-type":"print"},{"key":"ref14","series-title":"Patient Info: Fall Prevention"},{"key":"ref15","first-page":"CD001255","article-title":"Hip protectors for preventing hip fractures in the elderly","volume":"3","author":"Parker MJ","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1177\/000348949009900914","article-title":"Inhibition of osteoclast recruitment at a local site by 1-hydroxyethylidene-1,1-bisphosphonate (HEBP)","volume":"99","author":"Adachi K","year":"1990","journal-title":"Ann Otol Rhinol Laryngol","ISSN":"https:\/\/id.crossref.org\/issn\/0003-4894","issn-type":"print"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1172\/JCI114459","article-title":"Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro","volume":"85","author":"Carano A","year":"1990","journal-title":"J Clin Invest","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9738","issn-type":"print"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes DE","year":"1995","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of Risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis a randomized controlled trial: Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris ST","year":"1999","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref20","series-title":"Fosamax (Alendronate sodium) tablet and oral solution [prescribing information]","year":"2004"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Fracture Intervention Trial Research Group: Randomised trial of effect of Alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black DM","year":"1996","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of Alendronate on risk of fracture in women with low bone density but without vertebral fractures results from the Fracture Intervention Trial","volume":"280","author":"Cummings SR","year":"1998","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref23","series-title":"Actonel (Risedronate sodium tablets) [prescribing information]","year":"2004"},{"key":"ref24","series-title":"Boniva (Ibandronate sodium) tablets [prescribing information]","year":"2005"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral Ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut III CH","year":"2004","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study","volume":"65","author":"Reginster JY","year":"2006","journal-title":"Ann Rheum Dis","ISSN":"https:\/\/id.crossref.org\/issn\/0003-4967","issn-type":"print"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2005.12.017","article-title":"Preventing osteoporosis-related fractures: An overview","volume":"119","author":"Grass M","year":"2006","journal-title":"Am J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9343","issn-type":"print"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates a review of 63 cases","volume":"62","author":"Ruggiero SL","year":"2004","journal-title":"J Oral Maxillofac Surg","ISSN":"https:\/\/id.crossref.org\/issn\/0278-2391","issn-type":"print"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1385\/JCD:6:1:45","article-title":"Bone density changes with once weekly Risedronate in postmenopausal women","volume":"6","author":"Delaney MF","year":"2003","journal-title":"J Clin Densitom"},{"key":"ref30","first-page":"6","article-title":"Alendronate and Risedronate for the treatment of postmenopausal osteoporosis clinical profiles of the once-weekly and once-daily dosing formulations","volume":"6","author":"Emkey R","year":"2004","journal-title":"MedGenMed"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4158\/EP.8.3.202","article-title":"Response of bone mineral density to once-weekly administration of Risedronate","volume":"8","author":"Gordon MS","year":"2002","journal-title":"Endocr Pract"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","article-title":"Two-year results of once-weekly administration of Alendronate 70 mg for the treatment of postmenopausal osteoporosis","volume":"17","author":"Rizzoli R","year":"2002","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref33","first-page":"S448","article-title":"Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women?","volume":"19","author":"Cramer JA","year":"2004","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","article-title":"Treatment of postmenopausal osteoporosis","volume":"359","author":"Delmas PD","year":"2002","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Multiple Outcomes of Raloxifene Evaluation (MORE) investigators: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger B","year":"1999","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women results from the MORE [Multiple Outcomes of Raloxifene Evaluation] randomized trial","volume":"281","author":"Cummings SR","year":"1999","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene 4-year results from the MORE [Multiple Outcomes of Raloxifene Evaluation] trial","volume":"65","author":"Cauley JA","year":"2001","journal-title":"Breast Cancer Res Treat","ISSN":"https:\/\/id.crossref.org\/issn\/0167-6806","issn-type":"print"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw JE","year":"2002","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Women's Health Initiative Investigators: Effects of estrogen plus progestin on risk of fracture and bone mineral density the Women's Health Initiative randomized tria","volume":"290","author":"Cauley JA","year":"2003","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref40","series-title":"Forteo (teriparatide rDNA origin) injection 750 \u00b5g\/3 mL [prescribing information]","year":"2004"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer RM","year":"2001","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref42","series-title":"Miacalcin (calcitonin-salmon) nasal spray [prescribing information]","year":"2003"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"PROOF Study Group: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis the Prevent Recurrence of Osteoporotic Fractures Study","volume":"109","author":"Chesnut CH","year":"2000","journal-title":"Am J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9343","issn-type":"print"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1210\/er.2001-6002","article-title":"Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis: VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis","volume":"23","author":"Cranney A","year":"2002","journal-title":"Endocr Rev","ISSN":"https:\/\/id.crossref.org\/issn\/0163-769X","issn-type":"print"}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v50n4\/31876.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T12:42:57Z","timestamp":1495716177000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302006000400020&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0004-27302006000400020"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302006000400020","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}